Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

NASDAQ:CHEK opened at $2.23 on Wednesday. The firm’s fifty day simple moving average is $2.26 and its 200 day simple moving average is $2.53. Check-Cap has a twelve month low of $1.27 and a twelve month high of $4.63. The firm has a market capitalization of $13.02 million, a price-to-earnings ratio of -0.74 and a beta of 0.27.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.